Gender Differences in Coronary Risk Factors and Risk Interventions

  • Nanette K. Wenger


As was noted in the Framingham Heart Study [1,2], women develop any initial manifestations of coronary heart disease (CHD) approximately 10 years later than do men and incur myocardial infarction on average as much as 20 years later. With the aging of the US population and more women surviving to an older age when CHD becomes clinically manifest, several gender differences have been highlighted. The more adverse outcome has been prominent, with increased case fatality rates and greater morbidity of women after both myocardial infarction [2,3] and myocardial revascularization procedures. Since 1984, more women than men die of cardiovascular disease in the United States. This underscores the need to undertake preventive interventions at a younger age [4].


Coronary Heart Disease Coronary Risk Coronary Risk Factor Lipid Research Clinic Major Coronary Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heart and Stroke Statistical Update. Dallas: American Heart Association; 1997.Google Scholar
  2. 2.
    Kannel WB, Abbott RD: Incidence and prognosis of myocardial infarction in women: the Framingham Study. In Coronary Heart Disease in Women. Edited by Eaker ED, Packard B, Wenger NK, et al. New York: Haymarket Doyma Inc.; 1987: 208–214.Google Scholar
  3. 3.
    Abbott RD, Donahue RP, Kannel WB, et al.: The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988, 260: 3456–3460.PubMedCrossRefGoogle Scholar
  4. 4.
    Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. N Engl J Med 1993, 329: 247–256.PubMedCrossRefGoogle Scholar
  5. 5.
    Eaker ED, Chesebro JH, Sacks FM, et al.: Cardiovascular disease in women. Circulation 1993, 88: 1999–2009.PubMedCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control: Coronary heart disease incidence by sex-United States, 1971–1987. MMWR 1992, 41: 526–529.Google Scholar
  7. 7.
    Williams EL, Winkleby MA, Fortmann SP: Changes in coronary heart disease risk factors in the 1980s: evidence of a male-female crossover effect with age. Am J Epidemiol 1993, 137: 1056–1067.PubMedGoogle Scholar
  8. 8.
    Barrett-Connor EL, Cohn BA, Wingard DL, et al.: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991, 265: 627–631.PubMedCrossRefGoogle Scholar
  9. 9.
    Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979, 2: 120–126.PubMedCrossRefGoogle Scholar
  10. 10.
    Krolewski AS, Warram JH, Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90 (suppl 2A): 56s - 61s.PubMedCrossRefGoogle Scholar
  11. 11.
    Manson JE, Colditz GA, Stampfer MJ, et al.: A prospective study on maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151: 1141–1147.PubMedCrossRefGoogle Scholar
  12. 12.
    Liao Y, Cooper RS, Ghali JK, et al.: Sex differences in the impact of coexistent diabetes on survival in patients with coronary heart disease. Diabetes Care 1993, 16: 708–713.PubMedCrossRefGoogle Scholar
  13. 13.
    Donahue RP, Goldberg RJ, Chen Z, et al.: The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993, 46: 245–252.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldschmid MG, Barrett-Connor E, Edelstein SL, et al.: Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994, 89: 991–997.PubMedCrossRefGoogle Scholar
  15. 15.
    Modan M, Or J, Karasik A, et al.: Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation 1991, 84: 1165–1175.PubMedCrossRefGoogle Scholar
  16. 16.
    Hansen EF, Andersen LT, Von Eyben FE: Cigarette smoking and age at first acute myocardial infarction, and influence of gender and extent of smoking. Am J Cardiol 1993, 71: 1439–1442.PubMedCrossRefGoogle Scholar
  17. 17.
    Willett WC, Green A, Stampfer MJ, et al.: Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987, 317: 1303–1309.PubMedCrossRefGoogle Scholar
  18. 18.
    Perkins J, Dick TBS: Smoking and myocardial infarction: secondary prevention. Postgrad Med J 1985, 61: 295–300.PubMedCrossRefGoogle Scholar
  19. 19.
    Hermanson B, Omenn GS, Kronmal RA, et al., and Participants in the Coronary Artery Surgery Study: Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS Registry. N Engl J Med 1988, 319: 1365–1369.PubMedCrossRefGoogle Scholar
  20. 20.
    Coambs RB, Li S, Kozlowski LT: Age interacts with heaviness of smoking in predicting success in cessation of smoking. Am J Epidemiol 1992, 135: 240–246.PubMedGoogle Scholar
  21. 21.
    Rosenberg L, Kaufman DW, Heimrich SP, et al.: Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985, 253: 2965–2969.PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson CL, Rifkind BM, Sempos CT, et al.: Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993, 269: 3002–3008.PubMedCrossRefGoogle Scholar
  23. 23.
    Campos H, McNamara JR, Wilson PWF, et al.: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988, 67: 30–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Razay G, Heaton KW, Bolton CH: Coronary heart disease risk factors in relation to the menopause. Q J Med 1992, 85: 889–896.Google Scholar
  25. 25.
    Kannel WB: Nutrition and the occurrence and prevention of cardiovascular disease in the elderly. Nutr Rev 1988, 46: 68–78.PubMedCrossRefGoogle Scholar
  26. 26.
    Manolio TA, Pearson TA, Wenger NK, et al.: Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992, 2: 161–176.PubMedCrossRefGoogle Scholar
  27. 27.
    Castelli WP: The triglycerides issue: a view from Framingham. Am Heart J 1986, 112: 432–437.PubMedCrossRefGoogle Scholar
  28. 28.
    Bush TL, Criqui MH, Cowan LD, et al.: Cardiovascular disease mortality in women: results from the Lipid Research Clinics Follow-up Study. In Coronary Heart Disease in Women. Edited by Eaker ED, Packard B, Wenger NK, et al. New York: Haymarket Doyma Inc.; 1987: 106–111.Google Scholar
  29. 29.
    Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328: 1220–1225.PubMedCrossRefGoogle Scholar
  30. 30.
    Assmann G, Schulte H: The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992, 8 (suppl 1): 99–103.PubMedCrossRefGoogle Scholar
  31. 31.
    Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989, 79: 8–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Wong ND, Wilson PWF, Kannel WB: Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991, 115: 687–693.PubMedCrossRefGoogle Scholar
  33. 33.
    Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383–1389.Google Scholar
  34. 34.
    Lewis SJ, Sacks FM, Mitchell JS, et al. for the CARE Investigators: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Coll Cardiol 1998, 32: 140–146.PubMedCrossRefGoogle Scholar
  35. 35.
    Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279: 1615–1622.PubMedCrossRefGoogle Scholar
  36. 36.
    Barnard RJ: Effects of life-style modification on serum lipids. Arch Intern Med 1991, 151: 1389–1394.PubMedCrossRefGoogle Scholar
  37. 37.
    Anastos K, Charney P, Charon RA, et al.: Hypertension in women: what is really known? The Women’s Caucus, Working Group on Women’s Health of the Society of General Internal Medicine. Ann Intern Med 1991, 115: 287–293.PubMedCrossRefGoogle Scholar
  38. 38.
    National Center for Health Statistics: Health: United States, 1990. Hyattsville, MD: U.S. Public Health Service, Centers for Disease Control; 1991.Google Scholar
  39. 39.
    Hypertension Detection and Follow-up Program Cooperative Group: Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA 1988, 259: 2113–2122.CrossRefGoogle Scholar
  40. 40.
    Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race-sex and age. JAMA 1979, 242: 2572–2577.CrossRefGoogle Scholar
  41. 41.
    Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 1985, 291: 97–104.CrossRefGoogle Scholar
  42. 42.
    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255–3264.CrossRefGoogle Scholar
  43. 43.
    Barrett-Connor EL: Obesity, atherosclerosis and coronary artery disease. Ann Intern Med 1985, 103: 1010–1019.PubMedCrossRefGoogle Scholar
  44. 44.
    Spelsberg A, Ridker PM, Manson JE: Carbohydrate metabolism, obesity, and diabetes. In Cardiovascular Health and Disease in Women. Edited by Douglas PS. Philadelphia: WB Saunders Co.; 1993: 191–216.Google Scholar
  45. 45.
    Hubert HB, Feinleib M, McNamara PM, et al.: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67: 968–977.PubMedCrossRefGoogle Scholar
  46. 46.
    Brownell KD, Stunkard AJ: Differential changes in plasma high-density lipoprotein-cholesterol levels in obese men and women during weight reduction. Arch Intern Med 1981, 141: 1142–1146.PubMedCrossRefGoogle Scholar
  47. 47.
    Soler JT, Folsom AR, Kushi LH, et al.: Association of body fat distribution with plasma lipids, lipoprotein, apolipoproteins AI and B in postmenopausal women. J Clin Epidemiol 1988, 41: 1075–1081.PubMedCrossRefGoogle Scholar
  48. 48.
    Larsson B, Bengtsson C, Bjorntorp P, et al.: Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The Study of Men born in 1913 and the Study of Women, Goteborg, Sweden. Am J Epidemiol 1992, 135: 266–273.PubMedGoogle Scholar
  49. 49.
    Kannel WB, Sortie P: Some health benefits of physical activity. The Framingham Study. Arch Intern Med 1979, 139: 857–861.PubMedCrossRefGoogle Scholar
  50. 50.
    Blair SN, Kohl HW III, Paffenbarger RS Jr, et al.: Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989, 262: 2395–2401.PubMedCrossRefGoogle Scholar
  51. 51.
    Reaven PD, McPhillips JB, Barrett-Connor EL, et al.: Leisure time exercise and lipid and lipoprotein levels in an older population. J Am Geriatr Soc 1990, 38: 847–854.PubMedGoogle Scholar
  52. 52.
    Lokey EZ, Tran ZV: Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis. Int J Sports Med 1989, 10: 424–429.PubMedCrossRefGoogle Scholar
  53. 53.
    Hartung GH, Moore CE, Mitchell R, et al.: Relationship of menopausal status and exercise level to HDL cholesterol in women. Exp Aging Res 1984, 10: 13–18.CrossRefGoogle Scholar
  54. 54.
    Manson JE, Rimm EB, Stampfer MJ, et al.: Physical activity and incidence of non-insulin dependent diabetes mellitus in women. Lancet 1991, 338: 774–778.PubMedCrossRefGoogle Scholar
  55. 55.
    Mann JI, Inman WHW: Oral contraceptives and death from myocardial infarction. BMJ 1975, 2: 245–248.PubMedCrossRefGoogle Scholar
  56. 56.
    Mann JI, Vessey MP, Thorogood M, et al.: Myocardial infarction in young women with special reference to oral contraceptive practice. BMJ 1975, 2: 241–245.PubMedCrossRefGoogle Scholar
  57. 57.
    Mann JI, Inman WHW, Thorogood M: Oral contraceptive use in older women and fatal myocardial infarction. BMJ 1976, 2: 445–447.PubMedCrossRefGoogle Scholar
  58. 58.
    Shapiro S, Slone D, Rosenberg L, et al.: Oral-contraceptive use in relation to myocardial infarction. Lancet 1979, 1: 743–747.PubMedCrossRefGoogle Scholar
  59. Petitti DB, Wingerd J, Pellegrin F, et al.: Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979, 242:1150–1154.Google Scholar
  60. 60.
    Rosenberg L, Hennekens CH, Rosner B, et al.: Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol 1980, 111: 59–66.PubMedGoogle Scholar
  61. 61.
    Slone D, Shapiro S, Kaufman DW, et al.: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981, 305: 420–424.PubMedCrossRefGoogle Scholar
  62. 62.
    Royal College of General Practitioners’ Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet 1981, 1: 541–546.Google Scholar
  63. 63.
    Stampfer MJ, Willett WC, Colditz GA, et al.: A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med 1988, 319: 1313–1317.PubMedCrossRefGoogle Scholar
  64. 64.
    Stampfer MJ, Willett WC, Colditz GA, et al.: Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol 1990, 163: 285–291.PubMedCrossRefGoogle Scholar
  65. 65.
    Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991, 265: 1861–1867.PubMedCrossRefGoogle Scholar
  66. 66.
    Palmer JR, Rosenberg L, Shapiro S: Reproductive factors and risk of myocardial infarction. Am J Epidemiol 1992, 136: 408–416.PubMedGoogle Scholar
  67. 67.
    Knopp RH: The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol 1988, 72 (suppl 5): 23s - 30s.PubMedGoogle Scholar
  68. 68.
    Walsh BW, Schiff I, Rosner B, et al.: Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 1991, 325: 1196–1204.PubMedCrossRefGoogle Scholar
  69. 69.
    Barrett-Connor E, Laakso M: Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990, 10: 531–534.PubMedCrossRefGoogle Scholar
  70. 70.
    The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273: 199–208.CrossRefGoogle Scholar
  71. 71.
    Lafferty FW, Helmuth DO: Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects. Maturitas 1985, 7: 47–59.CrossRefGoogle Scholar
  72. 72.
    Stampfer MJ, Willet WC, Colditz GA, et al.: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985, 313: 1044–1049.PubMedCrossRefGoogle Scholar
  73. 73.
    Nachtigall LE, Nachtigall RH, Nachtigall RD, et al.: Estrogen replacement therapy, II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979, 54: 74–79.PubMedCrossRefGoogle Scholar
  74. 74.
    Hammond CB, Jelovsek FR, Lee KL, et al.: Effects of long-term estrogen replacement therapy. I: metabolic effects. Am J Obstet Gynecol 1979, 133: 525–536.PubMedGoogle Scholar
  75. 75.
    Bush TL, Barrett-Connor E, Cowan LD, et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75: 1102–1109.PubMedCrossRefGoogle Scholar
  76. 76.
    Talbott E, Kuller LH, Detre K, et al.: Biologic and psychosocial risk factors of sudden death from coronary disease in white women. Am J Cardiol 1977, 39:858–864.Google Scholar
  77. 77.
    Rosenberg L, Armstrong B, Jick H, et al.: Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976, 294: 1256–1259.PubMedCrossRefGoogle Scholar
  78. 78.
    Henderson BE, Paganini-Hill A, Ross RK: Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988, 159: 312–317.PubMedGoogle Scholar
  79. 79.
    Beard CM, Kottke TE, Annegers JF, et al.: The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year old women, 1969 through 1982. Mayo Clin Proc 1989, 64: 1471–1480.PubMedCrossRefGoogle Scholar
  80. 80.
    Petitti DB, Perlman JA, Sidney S: Noncontraceptive estrogens and mortality: long-term followup of women in the Walnut Creek study. Obstet Gynecol 1987, 70: 289–293.PubMedGoogle Scholar
  81. 81.
    Avila MH, Walker AM, lick H: Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990, 1: 128–135.CrossRefGoogle Scholar
  82. 82.
    Adam S, Williams V, Vessey MP: Cardiovascular disease and hormone replacement treatment: a pilot case-control study. BMJ 1981, 282: 1277–1278.PubMedCrossRefGoogle Scholar
  83. 83.
    Szklo M, Tonascia J, Gordis L, et al.: Estrogen use and myocardial infarction risk: a case-control study. Prey Med 1984, 13: 510–516.CrossRefGoogle Scholar
  84. 84.
    Rosenberg L, Slone D, Shapiro S, et al.: Noncontraceptive estrogens and myocardial infarction in young women. JAMA 1980, 244: 339–342.PubMedCrossRefGoogle Scholar
  85. 85.
    Thompson SG, Meade TW, Greenberg G: The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Commun Health 1989, 43: 173–178.CrossRefGoogle Scholar
  86. 86.
    LaVecchia C, Franceschi S, Decarli AS, et al.: Risk factors for myocardial infarction in young women. Am J Epidemiol 1987, 125: 832–843.Google Scholar
  87. 87.
    Wilson PWF, Garrison RJ, Castelli WP: Postmenopausal estrogen use and heart disease. N Engl J Med 1986, 315: 135.Google Scholar
  88. 88.
    Jick H, Dinan B, Rothman KJ: Noncontraceptive estrogens and nonfatal myocardial infarction. JAMA 1978, 239: 1407–1409.PubMedCrossRefGoogle Scholar
  89. 89.
    Stampfer MJ, Colditz GA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991, 325: 756–762.PubMedCrossRefGoogle Scholar
  90. 90.
    Sullivan JM, Vander Zwaag R, Hughes JP, et al.: Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990, 150: 2557–2562.PubMedCrossRefGoogle Scholar
  91. 91.
    Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 151: 75–78.PubMedCrossRefGoogle Scholar
  92. 92.
    Falkeborn M, Persson I, Adami H-O, et al.: The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynecol 1992, 99: 821–828.CrossRefGoogle Scholar
  93. 93.
    Hulley S, Grady D, Bush T, et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605— 613.Google Scholar
  94. 94.
    Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279: 1445–1451.PubMedCrossRefGoogle Scholar
  95. 95.
    Barrett-Connor E, Wenger NK, Grady D, et al.: Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Women’s Health 1998, 7: 839–847.PubMedCrossRefGoogle Scholar
  96. 96.
    Manson JE, Stampfer MJ, Colditz GA, et al.: A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991, 266: 521–527.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Nanette K. Wenger

There are no affiliations available

Personalised recommendations